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A B S T R A C T
Background: Elevated serum levels of cardiac troponin T (cTnT) and N-terminal fragment of B-type
natriuretic peptide (NT-proBNP), and also increased arterial stiffness/abnormal central hemodynamics,
are well-known risk factors for future cardiovascular events. The present study was conducted to clarify
which of the two – the serum level of cTnT or that of NT-proBNP – might be more closely associated with
the arterial stiffness/central hemodynamics.
Methods: In 2374 male employees of a company (46  9 years), the following parameters were measured:
second peak of the radial systolic pressure waveform (SP2), radial augmentation index (rAI), PP2 (SP2 minus
the diastolic blood pressure), brachial-ankle pulse wave velocity (baPWV), and serum levels of cTnT and
NT-pro BNP.
Results: After adjustments for confounding variables, binary logistic regression analyses demonstrated
that baPWV was associated with a signiﬁcant odds ratio for serum NT-proBNP 125 pg/mL (1.690; 95%
conﬁdence interval = 1.136–2.514, p = 0.002) and rAI was associated with a signiﬁcant odds ratio
for serum NT-proBNP 55 pg/mL (1.205; 95% conﬁdence interval = 1.012–1.435, p = 0.036). The baPWV,
rAI, SP2, and PP2 were not associated with signiﬁcant odds ratios for elevated serum cTnT levels
(0.014 ng/mL and 0.010 ng/mL).
Conclusions: In the middle-aged male worksite cohort studied, increased arterial stiffness/abnormal
central hemodynamics appeared to be associated with elevated serum NT-proBNP levels, rather than
with minimally elevated serum cTnT levels. This difference may be one of the plausible explanations for
the independency of the predictive values of the two serum markers for future cardiovascular events.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Elevated serum levels of cardiac troponin T (cTnT) reﬂect
myocardial damage, and the serum level of this protein was
originally used as a marker to predict the prognosis of patients
with acute coronary syndrome [1,2]. Recently, the high-sensitive
cTnT assay has been introduced in clinical settings [3–6], and with
its introduction, it has become possible to detect even small* Corresponding author at: Second Department of Internal Medicine, Tokyo
Medical University, 6-7-1 Nishi-Shinjuku, Tokyo 160-0023, Japan.
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population, and this parameter has been used as a marker to
predict future cardiovascular events [3–6]. However, the mecha-
nisms underlying the minimal elevations of the serum TnT are not
yet fully understood. On the other hand, increased arterial
stiffness/abnormal central hemodynamics have been much
focused on as independent risk factors for cardiovascular events
[7–10]. Bai et al. reported the existence of a correlation between
increased arterial stiffness, as reﬂected by the carotid-femoral
pulse wave velocity, and minimal elevations of the serum cTnT
levels in elderly Chinese subjects [11].
The Dallas Heart (DH) Study demonstrated that in middle-aged
subjects aged 40–70 years, minimal elevations of the serum cTnT
and elevated serum N-terminal fragment of B-type natriuretic reserved.
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future cardiovascular events [4]. The Atherosclerosis Risk in
Communities (ARIC) Study also reported similar ﬁndings [5]. While
several studies have demonstrated the existence of an association
between increased arterial stiffness/abnormal central hemody-
namics and elevated serum natriuretic peptide levels [12,13], no
study has clariﬁed the difference in the association with arterial
stiffness/central hemodynamics between serum cTnT levels and
serum NT-proBNP levels. Existence of such a difference might
serve as at least one of the explanations for the independency
of the predictive values of the two serum markers for future
cardiovascular events.
Previously, we reported the existence of a signiﬁcant
relationship between the arterial stiffness/central hemodynam-
ics and serum NT-proBNP levels in a middle-aged male worksite
cohort [12]. Then, in the same cohort of our previous study
(middle-aged male subjects working at a construction compa-
ny), the present cross-sectional study was conducted to clarify
whether increased arterial stiffness/abnormal central hemody-
namics might be associated as strongly with minimal elevations
of the serum cTnT levels as with elevations of the serum
NTproBNP levels.
Methods
Study cohort
The present cross-sectional study was conducted in a work-
site cohort composed of employees of a construction company
located in downtown Tokyo. The study protocol has already
been described in detail elsewhere [14]. The annual health
checkup conducted in the morning in fasting subjects included
physical examinations, blood pressure measurements (2 times)
with the subjects in the seated position, blood and urine
examinations, electrocardiography, chest roentgenography, bar-
ium swallow, audiometry, vision testing, and measurements of
the brachial-ankle pulse wave velocity (brachial-ankle PWV)
and radial augmentation index (radial AI). In 2012, in addition to
these examinations, the serum cTnT levels and serum NT-pro
BNP levels were also measured in all of the study subjects.
Verbal informed consent for the measurements was obtained
from all of the participants. The study was conducted with the
approval of the Ethics Guidelines Committee of Tokyo Medical
University.
Subjects falling under the following criteria were excluded from
the study [12,14,15]: (1) ankle/brachial systolic blood pressure
index of less than 0.95; (2) presence of atrial ﬁbrillation;
(3) standard deviation of the radial AI, calculated from ten radial
pressure waveform records, exceeding 6%.
Of the 2870 employees who were working at either the ofﬁce
headquarters or branch ofﬁces of the company located in Tokyo,
the data of 65 subjects were excluded because of the lack of
availability of the complete data set. In addition, 57 subjects
were excluded because they had an ankle/brachial systolic blood
pressure index of less than 0.95 (n = 13), atrial ﬁbrillation (n = 7),
or a standard deviation of the radial AI of 6% (n = 37) (some of
these subjects fulﬁlled more than two of the exclusion criteria).
Furthermore, 374 women were excluded because the number of
women in the study cohort was small. Finally, the data from
2374 men were included in the analyses.
Measurements
Pulse wave velocity
The brachial-ankle PWV was measured using a volume-
plethysmographic apparatus (Form/ABI, Colin Co. Ltd., Komaki,Japan), in accordance with a previously described methodology
[12,14]. In brief, occlusion cuffs, which were connected to both the
plethysmographic and oscillometric sensors, were tied around
both the upper arms and ankles of the subjects lying in the
supine position. The brachial and post-tibial arterial pressures
were measured using the oscillometric sensor. The measurements
were conducted after the subjects had rested for at least 5 min in
the supine position, in a temperature-controlled room (24–26 8C)
designed exclusively for this purpose.
Augmentation index
Measurements of the blood pressure and radial AI were
conducted after the subjects had rested for 5 min in the sitting
position. The blood pressure was measured in the right upper arm
using the oscillometric method (HEM-907; Omron Healthcare Co.,
Ltd., Kyoto, Japan). Immediately after this measurement, the left
radial arterial waveform was recorded using an arterial applana-
tion tonometry probe equipped with an array of 40 micropiezo-
resistive transducers (HEM-9010AI; Omron Healthcare Co., Ltd.).
The HEM-9010AI device is programmed to automatically deter-
mine the pressure of the radial artery to yield the optimal radial
arterial waveform [12,15]. Then, the ﬁrst and second peaks of the
peripheral systolic pressure [SBP1, a marker of the brachial systolic
blood pressure, and SBP2, a marker of the central systolic blood
pressure (CSBP)] and peripheral diastolic pressure (DBP) were
automatically detected using the fourth derivatives for each
radial arterial waveform, and averaged. The radial AI, a marker of
the central AI, was calculated as follows: (SBP2  DBP)/
(SBP1  DBP)  100 (%) [12,15]. PP1 = SBP1  DBP and PP2 =
SBP2  DBP, a marker of the central pulse pressure (CPP) were
calculated [12,15]. The mean blood pressure (MBP) was calculated
as 1/3 of the (SBP1  DBP) plus the DBP.
Laboratory measurements and deﬁnitions
The serum levels of total cholesterol (TC), triglyceride (TG),
high-density lipoprotein cholesterol (HDL) and creatinine (Crnn),
and the fasting blood glucose (FPG) were measured enzymatically
(Falco Biosystems Co. Ltd, Tokyo, Japan). Serum TnT levels were
measured using the Elecsys 2010 Troponin T hs kit (Roche
Diagnostics, Indianapolis, IN, USA) [16]. The lower limit of
detection is 0.008 ng/mL, with a reported 99th percentile value
in apparently healthy individuals of 0.014 ng/mL [16]. Serum
NT-pro BNP levels were determined using a chemiluminescence
immunoassay kit (Roche Diagnostics, Mannheim, Germany)
[17]. All the blood samples were obtained in the morning after
the patients had fasted overnight. The estimated glomerular
ﬁltration rate (eGFR) was calculated using the Modiﬁcation of
Diet in Renal Disease equation for Japanese subjects [18]: eGFR =
194  Crnn  1.094  Age  0.287.
Two cut-off points each were used to deﬁne elevations of the
serum TnT level (0.014 ng/mL and 0.010 ng/mL) [4,5,16,19]
and elevation of the serum NTproBNP level (125 pg/mL and
55 pg/mL) [17,20]. Diabetes mellitus was deﬁned as a history
of receiving medication for diabetes mellitus and/or glycated
hemoglobin A1C 6.5%. The current clinical histories of cardio-
vascular disease (coronary artery disease, other heart diseases,
and/or stroke) were obtained by questionnaires.
Statistical analysis
Data are expressed as means  SD. The relationships of the
arterial parameters with elevation of the serum cTnT and NT-proBNP
levels were assessed by binary logistic regression analyses. All of the
analyses were conducted using the IBM/SPSS software for Windows,
version 17.0J (IBM/SPSS Inc., Chicago, IL, USA); p-values < 0.05 were
considered to denote statistical signiﬁcance.
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Table 1 shows the clinical characteristics of the patients. The
prevalence rates of elevated minimal elevations of the serum cTnT
levels were as follows: 3.2% (76/2374) for the cut-off value
of 0.010 ng/mL, and 1.1% (26/2374) for the cut-off value of
0.014 ng/mL. The prevalence rates of elevated serum NT-proBNP
levels were as follows: 9.3% (221/2374) for the cut-off value of
55 pg/mL and 1.3% (31/2374) for the cut-off value of 125 ng/mL.
In the binary logistic regression analyses, advanced age,
reduced eGFR, elevated body mass index (BMI), and history
of medication for hypertension had signiﬁcant odds ratios for
elevated serum cTnT levels (0.014 ng/mL); advanced age,
reduced eGFR, elevated BMI, reduced HDL, elevated SP1 (brachial
systolic blood pressure), elevated PP1 (brachial pulse pressure),
history of smoking, presence of diabetes mellitus, and history
of medication for hypertension, dyslipidemia, and/or diabetesTable 1
Clinical characteristics of the study subjects.
Parameter
Age (years) 47  9
BMI (kg/m2) 24  3
Smoking (%) 54.3 (1290)
HR (beats/min) 68  10
baPWV (m/s) 13.2  2.0
rAI (%) 71  13
SP1 (mmHg) 121  14
SP2 (mmHg) 107  15
DBP (mmHg) 74  11
PP1 (mmHg) 47  8
PP2 (mmHg) 33  9
LDL (mmol/L) 2.89  0.44
TG (mmol/L) 2.25  0.76
HDL (mmol/L) 1.52  0.24
FPG (mmol/L) 4.88  0.41
Scr (mmol/L) 76  17
eGFR (mL/min per 1.73 m2) 79  13
cTnT (ng/mL) 0.008  0.002
cTnT 0.014 ng/mL (%) 1.1 (26)
cTnT 0.010 ng/mL (%) 3.2 (76)
NT-proBNP (pg/mL) 27  47
NT-proBNP 125 pg/mL (%) 1.3 (31)
NT-proBNP 55 pg/mL (%) 9.3 (221)
Percent (%) and no. of cases with CVD 2.7 (65)
Percent (%) and no. of cases with CHD 0.7 (16)
Percent (%) and no. of cases with other heart disease 1.6 (39)
Percent (%) and no. of cases with stroke 0.4 (10)
Percent (%) and no. of cases receiving med for HYP 14.6 (347)
Percent (%) and no. of cases receiving med for DL 7.0 (167)
Percent (%) and no. of cases receiving med for DM 7.3 (174)
BMI, body mass index; HR, heart rate; baPWV, brachial-ankle pulse wave
velocity; rAI, radial augmentation index; SP1, ﬁrst peak of the radial pressure
waveform (brachial systolic blood pressure); SP2, second peak of the radial
pressure waveform; BDP, brachial diastolic blood pressure; PP1, ﬁrst peak of the
radial pressure waveform–diastolic blood pressure; PP2, second peak of the
radial pressure waveform–diastolic blood pressure; LDL, serum low-density
lipoprotein cholesterol; HDL, serum high-density lipoprotein cholesterol; TG,
serum triglyceride; FPG, fasting plasma glucose; UA, serum uric acid level; Scr,
serum creatinine level; eGFR, creatinine-based estimated glomerular ﬁltration
rate; cTnT, serum level of cardiac troponin T; cTnT 0.014 ng/mL, number and
percentage of subjects with cTnT 0.014 ng/mL; cTnT 0.010 ng/mL, number
and percentage of subjects with cTnT 0.010 ng/mL; NT-proBNP, serum N-
terminal fragment B-type natriuretic peptide level; NT-proBNP 125 pg/mL,
number and percentage of subjects with NT-proBNP 125 pg/mL; NT-proBNP
55 pg/mL, number and percentage of subjects with NT-proBNP 55 pg/mL;
Percent and no. of, percentage and number of subjects; CVD, subjects with
cardiovascular disease (coronary heart disease, heart disease other than
coronary heart disease, and/or stroke); CHD, subjects with coronary heart
disease; Other heart disease, subjects with heart diseases other than coronary
heart disease; Med for HYP, subjects receiving medication for hypertension;
Med for DL, subjects receiving medication for dyslipidemia; Med for DM,
subjects receiving medication for diabetes mellitus; DM, subjects with diabetes
mellitus.mellitus had signiﬁcant odds ratios for elevated serum cTnT levels
(0.010 ng/mL) (Table 2). When these parameters were simulta-
neously entered in the binary logistic regression analyses,
advanced age, reduced eGFR, and elevated BMI were signiﬁcant
for serum cTnT levels 0.014 ng/mL, and advanced age, elevated
BMI, and history of medication for diabetes mellitus were
signiﬁcant for serum cTnT levels 0.010 ng/mL (Table 2). On the
other hand, a history of cardiovascular disease was not associated
with any signiﬁcant elevation of the odds ratio for elevated cTnT
levels.
For the case of elevated serum NT-proBNP levels, the binary
logistic regression analyses revealed advanced age, reduced eGFR,
elevated SP1, elevated PP1, history of smoking, and history of
medication for hypertension, dyslipidemia, and/or cardiovascular
diseases had signiﬁcant odds ratios for elevated serum NT-proBNP
levels 125 pg/mL; on the other hand, advanced age, reduced
eGFR, elevated SP1, elevated PP1, history of smoking, and history
of medication for hypertension and/or cardiovascular diseases
had signiﬁcant odds ratios for elevated serum NT-proBNP levels
55 pg/mL (Table 3). When these parameters were simultaneously
entered in the binary logistic regression analyses, advanced age,
reduced eGFR, history of smoking, and history of medication
for cardiovascular diseases were signiﬁcant for elevated serum
NT-proBNP levels 125 pg/mL, and advanced age and history
of medication for cardiovascular diseases were signiﬁcant for
elevated serum NT-proBNP levels 55 pg/mL (Table 3).
As shown in Table 4, while elevated brachial-ankle PWV
had a signiﬁcant odds ratio for elevated serum cTnT levels
(0.010 ng/mL) in the absence of adjustments, these associations
were no longer seen when the signiﬁcant variables were entered
simultaneously into a binary logistic regression analysis model.
On the other hand, when the signiﬁcant variables were entered
simultaneously into a binary logistic regression analysis model,
elevated brachial-ankle PWV was found to have a signiﬁcant
odds ratio for elevated serum NT-proBNP levels 125 pg/mL; in
addition, elevated radial AI also had a signiﬁcant odds ratio, and
elevated SP2 and PP2 had marginal odds ratios for elevated serum
NT-proBNP levels 55 pg/mL (Table 4).
Discussion
To the best of our knowledge, the present study is the ﬁrst
cross-sectional study to examine the signiﬁcance of the association
of elevated arterial stiffness/abnormal central hemodynamics
with minimally elevated serum cTnT levels as compared to that
with minimally elevated serum NT-proBNP levels in a middle-aged
male worksite cohort.
The cut-off values for minimal elevations of the serum cTnT
levels have not yet been clearly established [21]. The percentage of
subjects with minimally elevated serum cTnT levels was 6.7% in
the Prevention of Renal and Vascular End-stage Disease (PREVEND)
study (cut-off value 0.010 ng/mL) [19], 3.4% in the DH study (cut-
off value 0.014 ng/mL) [4], and 7.4% in the Atherosclerosis Risk in
Communities (ARIC) Study (cut-off value 0.014 ng/mL) [5]. In the
present study, the prevalence was 3.2% (76/2374) for the cut-off
value of 0.010 ng/mL, and 1.1% (26/2374) for the cut-off value of
0.014 ng/mL. The PREVEND study included study subjects with
renal dysfunction [18], and the mean age of the study subjects in
the DH study and ARIC study was higher than that in the present
study [4,5]. Aging and renal dysfunction are thought to be factors
associated with minimal elevations of the serum cTnT levels [3–6],
therefore, the prevalence rate of elevated serum cTnT levels in the
present study was lower than that in the PREVEND study [19], DH
study [4], and ARIC study [5].
The mechanisms underlying minimal elevation of serum cTnT
levels have not yet been fully clariﬁed. Bai et al. reported that
Table 2
Results of binary logistic regression analyses conducted to assess the associations of parameters other than markers of arterial stiffness/central hemodynamics with elevated serum cTnT levels.
Parameters Entered solely Entered simultaneously
Parameters B Wald p-value Odds 95% CI B Wald p-value Odds 95% CI
Elevation was deﬁned as serum cTnT levels 0.014ng/mL
Age (perSD) 0.749 12.557 <0.001 2.115 1.397–3.200 0.547 4.767 0.029 1.727 1.058–2.822
eGFR (perSD) 0.766 16.992 <0.001 0.465 0.323–0.669 0.601 7.123 0.008 0.548 0.353–0.852
BMI (perSD) 0.572 7.971 0.005 1.772 1.191–2.635 0.546 6.724 0.010 1.726 1.142–2.606
Smoking (0/1) 0.138 0.119 0.730 1.148 0.525–2.509 – – – – –
LDL (perSD) 0.296 1.645 0.200 0.744 0.473–1.169 – – – – –
HDL (perSD) 0.084 0.151 0.697 0.920 0.604–1.402 – – – – –
SP1 (perSD) 0.250 1.871 0.171 1.284 0.897–1.837 – – – – –
PP1 (perSD) 0.317 3.233 0.072 1.373 0.972–1.938 – – – – –
Med for HYP (0/1) 1.147 7.586 0.006 3.148 1.392–7.121 0.277 0.334 0.563 1.319 0.516–3.374
Med for DL (0/1) 0.643 0.395 0.530 0.526 0.071–3.905 – – – – –
Med for DM (0/1) 0.063 0.004 0.951 1.065 0.143–7.952 – – – – –
CVD (0/1) 0.356 0.120 0.729 1.427 0.190–10.698 – – – – –
DM (0/1) 0.507 0.671 0.413 1.661 0.494–5.586 – – – – –
Elevation was deﬁned as serum cTnT levels 0.010ng/mL
Age (perSD) 0.756 36.190 <0.001 2.129 1.664–2.723 0.838 19.828 <0.001 2.311 1.599–3.342
eGFR (perSD) 0.579 24.009 <0.001 0.560 0.445–0.707 0.253 2.329 0.127 0.777 0.561–1.075
BMI (perSD) 0.520 17.752 <0.001 1.682 1.321–2.143 0.436 7.446 0.006 1.546 1.131–2.115
Smoking (0/1) 0.746 8.472 0.004 2.109 1.276–3.486 0.187 0.364 0.546 1.206 0.656–2.217
LDL (perSD) 0.139 1.008 0.315 0.870 0.663–1.142 – – – – –
HDL (perSD) 0.320 5.733 0.017 0.726 0.559–0.944 0.207 1.754 0.185 0.813 0.598–1.105
SP1 (perSD) 0.379 12.773 <0.001 1.460 1.187–1.798 0.194 0.835 0.361 0.824 0.543–1.249
PP1 (perSD) 0.423 76.943 <0.001 1.527 1.248–1.867 0.320 3.135 0.077 1.377 0.966–1.962
Med for HYP (0/1) 1.226 24.591 <0.001 3.406 2.098–5.528 0.011 0.001 0.976 1.011 0.499–2.050
Med for DL (0/1) 0.953 8.570 0.003 2.592 1.370–4.905 0.033 0.005 0.943 0.968 0.399–2.347
Med for DM (0/1) 1.839 31.619 <0.001 6.289 3.313–11.939 1.493 4.136 0.038 4.452 1.008–18.213
CVD (0/1) 0.712 1.804 0.179 2.037 0.721–5.755 – – – – –
DM (0/1) 1.604 34.382 <0.001 4.972 2.909–8.499 0.110 0.030 0.863 0.896 0.257–3.129
Entered solely, parameters entered solely into binary logistic analysis; Entered simultaneously, parameters entered simultaneously into binary logistic analysis; B, non-standardized coefﬁcient; Wald, Wald chi-square; Odds,
odds ratio; 95% CI, 95% conﬁdence interval; perSD, as per standard deviation increase; 0/1, negative/positive; BMI, body mass index; SP1, ﬁrst peak of the radial pressure waveform (brachial systolic blood pressure); PP1, ﬁrst
peak of the radial pressure waveform–diastolic blood pressure; LDL, serum low-density lipoprotein cholesterol; HDL, serum high-density lipoprotein cholesterol; eGFR, creatinine-based estimated glomerular ﬁltration rate;
cTnT, serum level of cardiac troponin T; CVD, subjects with cardiovascular disease (coronary heart disease, heart disease other than coronary heart disease, and/or stroke); Med for HYP, subjects receiving medication for
hypertension; Med for DL, subjects receiving medication for dyslipidemia; Med for DM, subjects receiving medication for diabetes mellitus; DM, subjects with diabetes mellitus.
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Table 3
Results of binary logistic regression analyses carried out to assess the associations of parameters other thanmarkers of arterial stiffness/central hemodynamicswith elevated serumNTproBNP levels # Elevationwas deﬁned as serum
NT-proBNP levels 125pg/mL.
Parameters Entered solely Entered simultaneously
Parameters B Wald p-value Odds 95% CI B Wald p-value Odds 95% CI
Elevation was deﬁned as serum NT-proBNP levels 125pg/mL
Age (perSD) 0.967 22.026 <0.001 2.631 1.756–3.940 0.576 5.695 0.017 1.780 1.108–2.857
eGFR (perSD) 0.741 18.316 <0.001 0.477 0.340–0.669 0.391 4.069 0.044 0.677 0.463–0.989
BMI (perSD) 0.146 0.565 0.452 0.865 0.592–1.264 – – – – –
Smoking (0/1) 1.490 9.249 0.002 4.439 1.699–11.599 1.381 7.588 0.006 3.977 1.489–10.622
LDL (perSD) 0.011 0.003 0.956 0.989 0.661–1.480 – – – – –
HDL (perSD) 0.314 2.137 0.144 0.730 0.479–1.113 – – – – –
SP1 (perSD) 0.359 4.910 0.027 1.432 1.042–1.968 0.011 0.002 0.966 1.001 0.619–1.651
PP1 (perSD) 0.318 3.863 0.049 1.374 1.001–1.886 0.119 0.276 0.599 1.126 0.723–1.754
Med for HYP (0/1) 1.331 12.709 <0.001 3.786 1.821–7.871 0.351 0.651 0.420 1.420 0.606–3.327
Med for DL (0/1) 1.381 9.975 0.002 3.979 1.689–9.377 0.606 1.464 0.226 1.832 0.687–4.887
Med for DM (0/1) 0.122 0.014 0.905 0.885 0.119–6.570 0.973 0.820 0.365 0.378 0.046–3.105
CVD (0/1) 2.635 37.250 <0.001 13.950 5.984–32.518 1.979 17.555 <0.001 7.238 2.868–18.270
DM (0/1) 0.308 0.253 0.615 1.361 0.410–4.522 – – – – –
Elevation was deﬁned as serum NT-proBNP levels 55pg/mL
Age (perSD) 0.835 112.949 <0.001 2.304 1.975–2.688 0.685 58.157 <0.001 1.984 1.664–2.367
eGFR (perSD) 0.362 24.791 <0.001 0.696 0.604–0.803 0.091 1.278 0.258 0.913 0.779–1.069
BMI (perSD) 0.022 0.089 0.765 0.979 0.849–1.128 – – – – –
Smoking (0/1) 0.368 6.396 0.011 1.445 1.086–1.921 0.207 1.798 0.180 1.230 0.909–1.664
LDL (perSD) 0.094 1.276 0.259 0.910 0.773–1.072 – – – – –
HDL (perSD) 0.020 0.058 0.809 1.020 0.870–1.195 – – – – –
SP1 (perSD) 0.385 33.695 <0.001 1.469 1.290–1.673 0.117 1.404 0.236 1.125 0.926–1.366
PP1 (perSD) 0.294 19.575 <0.001 1.341 1.178–1.528 0.069 0.539 0.463 1.071 0.892–1.287
Med for HYP (0/1) 0.858 27.134 <0.001 2.358 1.708–3.257 0.050 0.072 0.789 1.051 0.729–1.515
Med for DL (0/1) 0.367 2.246 0.134 1.443 0.893–2.333 – – – – –
Med for DM (0/1) 0.001 0.000 0.998 0.999 0.476–2.097 – – – – –
CVD (0/1) 1.908 51.569 <0.001 6.738 4.003–11.341 1.502 27.484 <0.001 4.490 2.561–7.872
DM (0/1) 0.256 1.057 0.304 1.292 0.793–2.104 – – – – –
Entered solely, parameters entered solely into binary logistic analysis; Entered simultaneously, parameters entered simultaneously into binary logistic analysis; B, non-standardized coefﬁcient; Wald, Wald chi-square; Odds,
odds ratio; 95% CI, 95% conﬁdence interval; perSD, as per standard deviation increase; 0/1, negative/positive; BMI, body mass index; SP1, ﬁrst peak of the radial pressure waveform (brachial systolic blood pressure); PP1, ﬁrst
peak of the radial pressure waveform–diastolic blood pressure; LDL, serum low-density lipoprotein cholesterol; HDL, serum high-density lipoprotein cholesterol; eGFR, creatinine-based estimated glomerular ﬁltration rate;
cTnT, serum level of cardiac troponin T; CVD, subjects with cardiovascular disease (coronary heart disease, heart disease other than coronary heart disease, and/or stroke); Med for HYP, subjects receiving medication for
hypertension; Med for DL, subjects receiving medication for dyslipidemia; Med for DM, subjects receiving medication for diabetes mellitus; DM, subjects with diabetes mellitus.
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Table 4
Results of binary logistic regression analyses conducted to assess the correlations of markers of arterial stiffness/central hemodynamics with elevated serum cTnT levels and
elevated serum NT-proBNP levels.
Parameters Entered solely Adjusted with signiﬁcant parameters assessed by a binary
logistic regression analyses (i.e. age, eGFR, BMI, and Med for
HYP)
Parameters B Wald p-value Odds 95% CI B Wald p-value Odds 95% CI
Elevation was deﬁned as serum cTnT levels 0.014 ng/mL
baPWV (perSD) 0.240 1.985 0.159 1.271 0.910–1.775 – – – – –
rAI (perSD) 0.064 0.103 0.748 1.066 0.723–1.571 – – – – –
SP2 (perSD) 0.220 1.423 0.233 1.246 0.868–1.788 – – – – –
PP2 (perSD) 0.276 2.534 0.111 1.318 0.938–1.852 – – – – –
Parameters Entered solely Adjusted with signiﬁcant parameters assessed by a binary logistic
regression analyses (i.e. age, eGFR, BMI, Smoking, HDL, SP1, PP1,
Med for HYP, Med for DL, Med for DM, and DM)
Parameters B Wald p-value Odds 95% CI B Wald p-value Odds 95% CI
Elevation was deﬁned as serum cTnT levels 0.010 ng/mL
baPWV (perSD) 0.487 28.892 <0.001 1.628 1.363–1.945 0.177 1.042 0.307 1.194 0.849–1.678
rAI (perSD) 0.043 0.135 0.713 0.958 0.762–1.205 0.334 3.677 0.055 0.716 0.509–1.007
SP2 (perSD) 0.271 6.237 0.013 1.312 1.060–1.623 0.790 3.911 0.048 0.454 0.208–0.993
PP2 (perSD) 0.265 6.388 0.011 1.304 1.061–1.602 0.446 3.911 0.048 0.640 0.411–0.996
Parameters Entered solely Binary logistic regression analysis adjusted for signiﬁcant param-
eters (i.e. age, eGFR, Smoking, SP1, PP1, Med for HYP, Med for DL,
Med for DM, and CVD)
Parameters B Wald p-value Odds 95% CI B Wald p-value Odds 95% CI
Elevation was deﬁned as serum NT-proBNP levels 125 pg/mL
baPWV (perSD) 0.668 29.296 <0.001 1.950 1.531–2.483 0.525 6.709 0.010 1.690 1.136–2.514
rAI (perSD) 0.425 5.121 0.024 1.530 1.059–2.210 0.202 0.811 0.368 0.817 0.526–1.269
SP2 (perSD) 0.437 7.603 0.006 1.549 1.135–2.114 0.365 0.471 0.492 0.694 0.245–1.967
PP2 (perSD) 0.463 10.146 0.001 1.589 1.195–2.113 0.206 0.471 0.492 0.814 0.452–1.465
Parameters Entered solely Adjusted with signiﬁcant parameters assessed by a binary logistic
regression analyses (i.e. age, eGFR, Smoking, SP1, PP1, Med for HYP,
and CVD)
Parameters B Wald p-value Odds 95% CI B Wald p-value Odds 95% CI
Elevation was deﬁned as serum NT-proBNP levels 55 pg/mL
baPWV (perSD) 0.506 68.425 <0.001 1.658 1.471–1.869 0.132 2.132 0.144 1.141 0.956–1.361
rAI (perSD) 0.569 55.150 <0.001 1.766 1.520–2.052 0.187 4.391 0.036 1.205 1.012–1.435
SP2 (perSD) 0.499 57.303 <0.001 1.647 1.447–1.874 0.391 3.309 0.069 1.478 0.970–2.253
PP2 (perSD) 0.521 67.310 <0.001 1.684 1.487–1.907 0.221 3.309 0.069 1.247 0.983–1.582
Entered solely, parameters entered solely into binary logistic analysis; B, non-standardized coefﬁcient; Wald, Wald chi-square; Odds, odds ratio; 95% CI, 95% conﬁdence
interval; perSD, as per standard deviation increase; baPWV, brachial-ankle pulse wave velocity; rAI, radial augmentation index; SP2, second peak of the radial pressure
waveform; PP2, second peak of the radial pressure waveform–diastolic blood pressure.
K. Kimura et al. / Journal of Cardiology 66 (2015) 135–142140increased arterial stiffness, as assessed by the carotid-femoral
PWV, is associated with minimally elevated serum cTnT levels in
elderly subjects (aged >60 years old), but not in middle-aged
subjects (aged <60 years old) [11]. Pathophysiological abnormali-
ties (i.e. increased left ventricular afterload, including increased
late systolic left ventricular wall stress and impaired coronary
blood ﬂow supply) related to increased arterial stiffness/abnormal
central hemodynamics may be responsible for elevation of the
serum cTnT levels. The AI, SP2, and PP2 are markers of central
hemodynamics [12,15], and these markers reﬂect facets of
pathophysiological abnormalities different from those reﬂected
by the PWV, a marker of arterial stiffness [12,15,22–24]. SP2 is a
marker related to left ventricular afterload, and PP2 is a marker
related to left ventricular wasted effort and ejection duration
(these abnormalities cause myocardial ischemia) [12,15,
22–25,13], which is a major risk factor for heart failure and left
ventricular hypertrophy. While the DH study demonstrated that
heart failure and left ventricular hypertrophy are associated with
minimally elevated serum cTnT levels [4], Bai et al. did not examine
the association of the AI, SP2, or PP2 with the serum cTnT levels
[11]. In the present study, not only the brachial-ankle PWV, but
also the radial AI, SP2, and PP2 did not show any signiﬁcant
association with the serum cTnT levels. Thus, in the middle-agedmale worksite cohort, arterial stiffness/central hemodynamics
did not appear to be signiﬁcant determinants of minimally
elevated serum cTnT levels.
Several studies have reported that aging, elevated blood
pressure, diabetes mellitus, and renal dysfunction are associated
with minimally elevated serum cTnT levels [3–6], and also with
increased arterial stiffness/abnormal central hemodynamics
[22,24]. In the present study, advanced age, elevated BMI,
hypertension, and reduced GFR, but not elevated brachial-ankle
PWV, SP2, or PP2, were associated with minimally elevated serum
cTnT levels. Therefore, conventional risk factors for cardiovascular
disease and renal dysfunction might be directly associated with
coronary microvascular damage/cardiac myocyte damage, and
such damage might also contribute to minimally elevated serum
cTnT levels, according to the results of the present study.
The DH study and ARIC study demonstrated that elevated
serum cTnT levels and elevated serum NT-proBNP levels are
independent predictors of future cardiovascular events [4,5]. Pre-
viously, we demonstrated that elevated PP2, a marker related to
central pulse pressure, was associated with elevated serum NT-
proBNP levels [12]; similar ﬁndings were observed in the present
study in that the brachial-ankle PWV and radial AI showed a
signiﬁcant relationship with the serum NT-proBNP levels. Thus,
K. Kimura et al. / Journal of Cardiology 66 (2015) 135–142 141increased arterial stiffness/abnormal central hemodynamics may
contribute, at least in part, to the association of elevated serum NT-
proBNP levels with cardiovascular events. On the other hand,
increased arterial stiffness/abnormal central hemodynamics may
not contribute to the known association of minimally elevated
serum cTnT levels with cardiovascular events.
Our previous study reported that among the markers of
arterial stiffness/central hemodynamics, PP2 showed the closest
relationship to the serum NT-proBNP levels in healthy middle-
aged men, not including patients with cardiovascular disease
[12]. The present study subjects included patients with
cardiovascular disease, which might be one of the plausible
reasons why elevated brachial-ankle PWV and radial AI, but not
elevated PP2, showed signiﬁcant odds ratios for elevated serum
NT-proBNP levels.
From the clinical perspective, in the present study, elevated
serum NT-proBNP levels, but not elevated serum cTnT levels, were
associated with cardiovascular disease. In previous studies that
reported the usefulness of serum cTnT levels to predict future
cardiovascular events, all the study subjects were over 50 years of
age [3–6]. Thus, in middle-aged men, serum cTnT may not be a
suitable marker for screening against latent cardiovascular disease
in a health check-up program.
Study limitations
(1) This was a cross-sectional study, and a prospective study to
examine the interactions among the predictive values of the
serum cTnT levels, serum NT-proBNP levels, and markers of
arterial stiffness/central hemodynamics for predicting future
cardiovascular events is proposed.
(2) Although the carotid-femoral PWV and carotid arterial wave
analysis are the standards for non-invasive assessment of the
arterial stiffness/central hemodynamics [7,9], we used brachi-
al-ankle PWV and radial arterial waveform analysis, because of
the simplicity of their application to a large number of study
subjects [8,12,14,15].
(3) Gender and ethnic differences in the central hemodynamic
indices have been reported [14,25]. On the other hand, the
usefulness of serum cTnT to predict future cardiovascular
events and/or the prognosis has been demonstrated in a
general population consisting of relatively old subjects,
subjects with acute pulmonary edema and subjects with acute
chest pain [3–6,26,27]. Therefore, evaluations of the associa-
tions among the serum cTnT levels, arterial stiffness/central
hemodynamics, and the risk/prognosis of cardiovascular
disease/the prognosis of cardiovascular disease in women
and elderly subjects, and also subjects of other ethnicities and
with cardiovascular disease are proposed.
Conclusion
Increased arterial stiffness/abnormal central hemodynamics
appeared to be associated with elevated serum NT-proBNP levels,
rather than with minimally elevated serum cTnT levels, in the
middle-aged male worksite cohort studied. This difference may
be one of the plausible explanations for the independence of
the predictive values of the two serum markers for future
cardiovascular events.
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